Navigation Links
Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:9/16/2009

ds and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential FDA marketing approval for KRYSTEXXA(TM) (pegloticase), whether any further clinical trials will be required, the actions that may be required of Savient by the FDA in connection with the BLA, the reversion to and revalidation of the Phase 3 manufacturing process, the timing of a resubmission to the FDA in response to the complete response letter and the efficacy and safety of KRYSTEXXA are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data, our current understanding of the complete response letter and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the possibility that the FDA may raise further issues regarding the BLA for KRYSTEXXA or require that we conduct additional clinical trials, our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
2. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
7. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Savient Submits Biologics License Application (BLA) for pegloticase
9. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
10. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
11. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Government ... Order and ... of,advanced technology solutions for homeland and military security, announced,today a ... of airborne biological threats. The AirSentinel,sensors, developed with support from ...
... EPI-Q, Inc., a consulting firm,providing outcomes research ... healthcare industries, announces the addition of,Anthony J. Vita, ... team of clinical,professionals. The specialized background of these ... to offer directly to those clients,seeking to enhance ...
... -,- 3Q07 Net Income Increased 58% Compared to 3Q06 to $11.9 Million, or ... ... Provides Financial Outlook for 2007 and 2008 -, NEW YORK, Nov. 5 ... of,plant-based pharmaceutical and nutraceutical products, today announced,financial results for the third quarter of ...
Cached Biology Technology:ICx Awarded Department of Defense Contract for AirSentinel Monitors 2EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... stem cells can develop into a multitude of cells types. ... into the specific types of mature cells that make up ... One key seems to be long chains of sugars that ... group at the University of California, San Diego, has created ... but can be more easily manipulated to direct the process, ...
Breaking Biology News(10 mins):
... Australian medical research has given pregnant women with epilepsy new ... physical birth defects. According to research published in the ... of the American Academy of Neurology, epilepsy experts at ... doses of common epilepsy drug valproate and the increased risk ...
... Medicine and Dentistry has received an award of 94,365 ... Reduction of Animals in Research (NC3Rs), for a pilot study ... cell which could be used in place of the live ... Macrophages are crucial components of the immune system and ...
... 22, 2013   Valid USA continues the expansion ... that it has acquired ScreenCheck North America (SCNA) ... the worldwide exclusive licensee for Polaroid ® identification ... to provide AAMVA compliant Real ID solutions. SCNA also ...
Cached Biology News:Epilepsy drug dosage linked to specific birth defects 2Funding for animal testing alternative 2Valid USA Continues Growth with Acquisition of ScreenCheck North America 2